Amr El-Shamy

Results-oriented achiever with proven ability to exceed targets and drive success in fast-paced environments. Combines strategic thinking with hands-on experience to deliver impactful solutions and enhance organizational performance. Detail-oriented individual with exceptional communication and project management skills. Proven ability to handle multiple tasks effectively and efficiently in fast-paced environments. Recognized for taking proactive approach to identifying and addressing issues, with focus on optimizing processes and supporting team objectives.

• Date of Birth: 12/06/88
• Gender: Male
• Nationality: Egyptian
• Driving License: Valid
• Marital Status: Married

Patient Access

Reimbursements
 Jan 2021 securing the expansion of Tresiba® & Victoza® in Kuwait PHCs.
 March 2021 Enlisting of Xultophy® In MOH secondary care.
 March 2022 enlisting of Ryzodeg® in Kuwait MOH secondary care.
 May 2022 Rybelsus® reimbursement in Private Health insurance ( AFYA & others )
 June 2023 Securing access approvals for Xultophy® & Ryzodeg® Kuwait MOH-PHCs.
 Aug 2023 Ozempic® reimbursement in Private Health insurance ( AFYA & others )
 Jan 2024 enlisting of Rybelsus® in Kuwait MOH secondary care.
 Feb 2024 enlisting of Ozempic® in Kuwait MOH secondary care.

Access Supporting Projects
 Induction of 6 weeks diabetes certificate course for primary care in Kuwait supporting more than 120 HCP.
 Induction of 1 Year diabetes diploma from Harvard for 30 senior HCPs in Kuwait primary care.
 Localizing with the regional office SEEMEA (Southeast Europe, Middle East & Africa) a value tool to calculate Obesity burden cost and cost of associated comorbidities.
 Development and production of NCD (Non-communicable diseases) Guidelines in Primary Health Care - Kuwait MOH in 2 forms (Mobile App – Hard copies).
 Authoring “The economic impact of obesity in Kuwait: A micro-costing study evaluating the burden of obesity-related complications” original research - The first ever in Kuwait an Obesity local Health Economic research - Click here.
 Obesity epidemiology study (multicenter, retrospective, disease area study aiming to assess the prevalence of the most Obesity Related Complications (ORCs) and to describe the annual Health Care Resource Utilization (HCRU) and associated costs among People with Obesity in the primary and secondary care setting across Kuwait, Qatar & Oman).

Public Affairs
 June 2021 first of a kind event 100 Year Insulin celebration in Kuwait gathering 20 policymakers to roadmap the diabetes management in Kuwait, meeting outcome will be a white paper on how to advance diabetes care in Kuwait.
 Paving the way for Novo Nordisk Mega Global Project City Changing Diabetes and securing the Ass. Undersecretary endorsement for the project to be lunched in Kuwait.
 Participating with Kuwait obesity policy makers in OPEN GULF CONNECT regional meeting to share what had been done since OPEN GULF in 2019 1st wave and agree on the next steps per country in preparation for the 2nd wave in May 2022.
 Partnership with Kuwait MOH- PHC to launch 5 weeks Obesity awareness campaign covering whole Kuwait.
 Partnership with Kuwait MOH to develop Obesity National protocol for diagnoses and treatment.
 Liaising between Kuwait MOH- PHC & secondary care in unifying referral system for people with Obesity and activation of Obesity clinics.
 July 2022 official recognition of Obesity as a disease in Kuwait.
 22nd Nov 22 Launch new Kuwait diabetes policy (Roadmap for the prevention and control of diabetes in Kuwait) in the occasion of the world diabetes day and 100years of insulin anniversary in collaboration with MOH, Royal Danish Embassy, World Health Organization, Dasman Diabetes institute & Kuwait diabetes society.

Sales Achievements
 2019 Gulf Cluster Biopharm best achiever & AAMEO (Africa, Asia, Middle East, Oceana) Biopharm Champion.
 YTD 100 %, 100 %, 137 %, 120 % achievement total value in 2017, 2018, 2019, 2020 respectively at Novonordisk- Kuwait.
 YTD 133 % Achievement total value, at Sanofi – Kuwait.
 YTD 90 % Achievement total value, at Takeda – Kuwait.
 YTD 110 % Achievement total value, at Boehringer Ingelheim – Saudi Arabia.
 YTD 127 % achievement total value, At MSD - Egypt. also, I got 2nd place in MSD National Competition of Univadis Project and the 1st in my business unit.